UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   Form 10-QSB

      X    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
      EXCHANGE ACT OF 1934

               For the quarterly period ended September 30, 2002

      _    TRANSITION  REPORT  UNDER  SECTION  13 OR  15(d)  OF THE  SECURITIES
           EXCHANGE ACT OF 1934
                     For the transition period from           to
                        Commission File Number 000-24541

                         CORGENIX MEDICAL CORPORATION
                (Name of Small Business Issuer in its Charter)


              Nevada                           93-1223466
  (State or other jurisdiction of    (I.R.S. Employer Identification
  incorporation or organization)                  No.)


                12061 Tejon Street, Westminster, Colorado 80234

         (Address of principal executive offices, including zip code)

                                 (303) 457-4345

               (Issuer's telephone number, including area code)

      (Former  name,  former  address and former  fiscal year, if changed since
      last report)

Check  whether  the  issuer:  (1) filed  all  reports  required  to be filed by
Section  13 or 15(d) of the  Exchange  Act  during  the past 12 months  (or for
such shorter  period that the  registrant  was required to file such  reports),
and  (2)  has  been  subject  to  such  filing  requirements  for  the  past 90
days.     Yes X   No  ___
              -

The number of shares of Common Stock outstanding was 5,219,076 as of November
14, 2002.

Transitional Small Business Disclosure Format.     Yes _   No X
                                                              -

<PAGE>




                          CORGENIX MEDICAL CORPORATION


                               September 30, 2002





                                TABLE OF CONTENTS


                                                                  Page


                                     Part I


                              Financial Information


      Item 1.   Consolidated Financial Statements                   3


      Item 2.   Management's  Discussion  and Analysis of
                Financial  Condition and Results of
                Operations                                         10



      Item 3.   Controls and Procedures                            14




                                     Part II


                                Other Information


      Item 1.   Legal Proceedings                                  19


      Item 2.   Changes in Securities and Use of Proceeds          19


      Item 3.   Defaults Upon Senior Securities                    19


      Item 4.   Submission of Matters to a Vote of Security
                Holders                                            19


      Item 5.   Other Information                                  19


      Item 6.   Exhibits and Reports on Form 8-K                   20


      Certifications                                               23




<PAGE>


                                     PART I
                   Item 1. Consolidated Financial Statements
                          CORGENIX MEDICAL CORPORATION
                                AND SUBSIDIARIES
Consolidated Balance Sheets
-------------------------------------------------------------------------------


                                     September 30, 2002      June 30, 2002
                                         (Unaudited)
                Assets
Current assets:
  Cash and cash equivalents               $379,423               164,378
  Accounts receivable, less allowance for
      doubtful accounts of  $15,000 and
      $30,000                              749,096               694,394
  Inventories                              697,641               665,305
  Prepaid expenses                          49,280                44,836
                                          --------               --------
                Total current assets     1,875,440             1,568,913
Equipment:

  Capitalized software costs               122,855               113,261
  Machinery and laboratory equipment       513,698               513,698
  Furniture, fixtures, leaseholds
      & office equipment                   452,694               448,743
                                          --------               -------
                                         1,089,247             1,075,702

  Accumulated depreciation and
      amortization                        (670,046)             (642,285)
                                          ---------             ---------
                  Net equipment            419,201               433,417
                                          ---------             ---------
Intangible assets:
  Patents, net of accumulated
       amortization of  $889,106
       and $870,482                        228,438               247,062
  Goodwill, net of accumulated
       amortization of  $44,979             13,677                13,677
                                           --------              --------
                   Net intangible assets   242,115               260,739
                                           --------              --------
  Due from officer                          12,000                12,000
  Other assets                              71,814                53,766
                                           --------              --------
                   Total assets         $2,620,570             2,328,835
                                        ===========            =========

                 Liabilities and Stockholders' Equity (Deficit)
Current liabilities:
  Accounts  payable                    $   294,145               553,505
  Accrued payroll and
       related liabilities                 139,998               118,155
  Accrued liabilities                       44,545                24,938
  Accrued interest                         105,275                98,764
  Current portion of  notes payable        286,457               357,672
  Current portion of capital
       lease obligations                    91,352                92,554
                                           -------                -------

                    Total current
                    liabilities            961,772             1,245,588

Notes payable, excluding current portion   472,334               502,611
Capital lease obligations, excluding
    current portion                         82,715                99,898
                                           --------              -------

                  Total liabilities      1,516,821             1,848,097
                                        -----------           -----------

Redeemable common stock, 880,282 shares
       Issued and outstanding, aggregate
       redemption value of $500,000,
       net of  unaccreted discount and
       issuance costs of  $206,278
       at September 30, 2002               292,736                 -
Stockholders' equity (deficit):
  Preferred stock, $0.001 par value.
       Authorized 5,000,000 shares,
       none issued or outstanding            -                     -
  Common stock, $0.001 par value.
       Authorized 40,000,000 shares;
       issued  and outstanding
       and 4,333,095 on September 30
       and June 30,  respectively            4,339                4,333
Additional paid-in capital               4,921,590            4,695,392
Accumulated deficit                     (4,122,898)          (4,250,915)
Accumulated other comprehensive income       7,982               31,928
                                        -----------           ----------

      Total stockholders' equity           811,013              480,738

 Total liabilities and stockholders'
 equity                                 $2,620,570            2,328,835
                                        ===========          ===========

See accompanying notes to consolidated financial statements.


<PAGE>



                          CORGENIX MEDICAL CORPORATION
                                AND SUBSIDIARIES

Consolidated Statements of Operations

-------------------------------------------------------------------------------

                                       Three Months Ended

                                       September September
                                       30,          30,
                                         2002      2001
                                       --------------------

(Unaudited)         (Unaudited)


Net sales                           $1,410,040   1,151,062
Cost of sales                          411,820     316,669
                                       -------   ---------


          Gross profit              $  998,220     834,393


Operating expenses:
  Selling and marketing                309,016     233,091

  Research and development              209,982    138,721

  General and administrative            300,419    292,040

   Expenses of consumer healthcare
   business                               -        37,196
                                       --------- ----------

  Total expenses                        819,417   701,048
                                       ---------   -------


          Operating income          $   178,803   133,345


Interest expense, net                    30,058    34,852
                                       ---------  --------


Net income                          $   148,745    98,493


Accretion of discount on redeemable      20,728      -
common stock                           ---------   --------


Net income to common shareholders   $   128,017    98,493
                                       ==========  ========


 Net income per common share, basic $      0.02      0.01


 Net income per common share, diluted $    0.02      0.01


Weighted average shares outstanding,  5,209,322  4,193,576
basic                                 =========  =========


Weighted average shares outstanding,  5,209,322  4,228,968
 diluted                              =========  =========

          Net income (loss)           $ 148,745     98,493


 Other comprehensive income
 (loss)-foreign currency
 translation loss                       (23,946)   (11,071)
                                      ----------  ---------

 Total comprehensive income            $124,799     87,422
                                       =========    =======

See accompanying notes to consolidated financial statements.



<PAGE>


                          CORGENIX MEDICAL CORPORATION
                                AND SUBSIDIARIES



Consolidated Statements of Cash Flows
-------------------------------------------------------------------------------

                                                       Three Months
                                                           Ended
                                               September 30,    September  30,
                                                   2002              2001
                                               -------------------------------
                                                (Unaudited)      (Unaudited)
 Cash flows from operating activities:
  Net income                                   $  148,745           98,493
  Adjustments to reconcile net income to
 net cash used in operating activities:

             Depreciation and amortization         46,385           90,016

             Equity instruments issued
             for services                           3,419           10,619
             Changes in operating assets
and liabilities:
                  Accounts receivable, net        (54,702)         (28,948)
                  Inventories                     (32,336)         (65,976)
                  Prepaid expenses and
                  other assets                    (22,492)         (15,598)
                 Accounts payable                (259,360)        (178,995)
                 Accrued payroll and
                 related liabilities               21,843          (20,230)
                 Employee stock purchase
                 plan payable                        (586)             416
                 Accrued interest and
                 other liabilities                 26,704           39,537
                                                 ----------      ----------

                    Net cash used in operating
                    activities                   (122,380)         (70,666)
                                                 ---------        ---------

Cash flows used by investing activities:
   Additions to equipment                         (13,545)          (2,065)

Cash flows from financing activities:
  Proceeds from issuance of redeemable
common stock and warrants                         500,000          175,615
  Proceeds from issuance of notes payable          19,100            1,334
  Payments on notes payable                      (120,592)         (32,414)
  Payments on capital lease obligations           (18,385)         (12,068)
  Payments for costs of issuance of
        common stock                               (5,207)         (15,707)

        Net cash provided by financing
        activities                                374,916          116,760
                                                 ----------    ------------

        Net increase in cash and cash equivalents 238,991           44,029

Impact of foreign currency translation
adjustment on cash                                (23,946)         (11,071)

Cash and cash equivalents at beginning of
period                                            164,378          320,140
                                                  ---------     -----------
Cash and cash equivalents at end of period     $  379,423          353,098
                                               ------------     -----------
Supplemental cash flow disclosures:

  Cash paid for interest                       $   16,425           29,014
Noncash investing and financing activity--
   Equipment acquired under capital leases
                                               $      -             40,000
                                               ------------     ------------
See accompanying notes to consolidated financial statements.




<PAGE>



                 CORGENIX MEDICAL CORPORATION AND SUBSIDIARIES

                  NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.    DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

On May 22, 1998, REAADS Medical Products (REAADS) completed a merger with a
subsidiary of Gray Wolf Technologies, Inc., an inactive corporation with no
significant assets or operations. The resulting merged corporation was named

Corgenix, Inc. The parent corporation was renamed Corgenix Medical Corporation
(Corgenix or the Company).Corgenix Medical Corporation (Corgenix or the Company)
develops, manufactures and markets diagnostic products for the serologic
diagnosis of certain vascular diseases and autoimmune disorders using
proprietary technology. We market our products to hospital laboratories and
freestanding laboratories worldwide through a network of sales representatives,
distributors, and private label (OEM) agreements. Our headquarter offices and
manufacturing facility are located in Westminster, Colorado.

The consolidated financial statements include the accounts of the Company, its
wholly owned subsidiaries, Corgenix, Inc. and Corgenix UK Limited (Corgenix UK),
and untilJune of 2002, the accounts of healthoutfitters.com, Inc. ("Ho.com").
Corgenix UK was established as a United Kingdom company during 1996 to market
the Company's products in Europe. Transactions are generally denominated in US
dollars. Ho-com managed an internet-based healthcare business. The e-commerce
internet site, www.sports-n-fitness.com became operational in the quarter ended
June 30, 2001. The site was a consumer-focused interactive site including
healthcare-related products available for convenient purchase and delivery and
links to numerous other healthcare information sites. In June 2002, the Company
determined that its consumer healthcare business and associated operations via
consumer websites were not strategic to the Company's ongoing objectives and
core medical diagnostic kit business. Accordingly, during the fourth quarter of
fiscal 2002, the Company decided to abandon and close its internet-based
consumer business and all related e-commerce sites managed and operated by
Ho.com. Assets abandoned principally consisted of unamortized capitalized
software costs.

The accompanying consolidated financial statements have been prepared without
audit and in accordance with generally accepted accounting principles for
interim financial information and with the instructions to Form 10-QSB and
Article 10 of Regulation S-X. Accordingly, they do not include all of the
information and footnotes required by generally accepted accounting principles
for complete financial statements. In the opinion of the Company, the financial
statements include all adjustments (consisting of normal recurring accruals and
adjustments) required to present fairly the Company's financial position at
September 30, 2002 and June 30, 2002 and the results of operations for each of
the three month periods ended September 30, 2002 and 2001, and the cash flows
for each of the three month periods then ended. The operating results for the
three months ended September 30, 2002 are not necessarily indicative of the
results that may be expected for the year ended June 30, 2003. For further
information, refer to the consolidated financial statements and footnotes
thereto included in the Company's annual report on Form 10-KSB for the fiscal
year ended June 30, 2002.

Management of the Company has made a number of estimates and assumptions
relating to the reporting of assets and liabilities and the disclosure of
contingent assets and liabilities to prepare these
financial statements in conformity with accounting principles generally accepted
in the United States of America. Significant assumptions inherent in the
preparation of the accompanying financial statements include, but are not
limited to, revenue recognition and allowances for doubtful accounts, the
provision for excess and obsolete inventories, and commitments and
contingencies. Actual results could differ from those estimates.

2. SOFTWARE

The Company accounts for its software and information technology in
compliance with Statement of Position 98-1 ("SOP 98-1"), Accounting for the
Costs of Computer Software Developed or Obtained for Internal Use. SOP 98-1
defines the types of computer software project costs that may be capitalized.
All other costs are expensed in the period incurred. In order for costs to be
capitalized, the computer software project must be intended to create a new
system or add identifiable functionality to an existing system.In the fourth
quarter of fiscal 2001, the Company established an internet-based consumer
healthcare business which consisted primarily of an e-commerce internet site for
selling medical and health products directly to consumers. Direct internal and
external costs of developing the software, other than initial design, were
capitalized and began to be amortized on the straight-line method over three
years starting in the first quarter of fiscal year 2002. See (1) above, for a
discussion regarding the abandonment and closure of the Company's internet-based
consumer health care business. Amortization of $49,659 was recorded on such
assets for the quarter ended September 30, 2001. No comparable amortization was
recorded during the latest quarter.In the quarter ended December 31, 2001, the
Company began development of a business-to-business web site (Corgenix On Line)
for its core business reference laboratory and hospital customers and potential
customers worldwide. The website, when completed, will allow customers to place
orders for the Company's diagnostic products, pay for said orders, and track the
status of such orders. It will also give full specification and details on all
of the Company's diagnostic test kits. The direct internal and external costs of
developing the related software, other than initial design and other costs
incurred during the preliminary project stage, have been capitalized and will
continue to be capitalized until the software has been completed. To date, all
products and enhancements thereto have utilized proven technology. Such
capitalized amounts, $122,855 as of September 30, 2002, will be amortized on a
straight line basis over a three-year period commencing when the website is
placed in service, which is expected to be in October 2002.

3. EARNINGS PER SHARE

Basic earnings per share is computed by dividing net income by the weighted
average number of common shares outstanding. Diluted earnings per share is
computed by dividing net income by the weighted average number of common shares
outstanding increased for potentially dilutive common shares outstanding during
the period. The dilutive effect of stock options and their equivalents is
calculated using the treasury stock method. For the quarters ended September 30,
2002 and 2001, options and warrants to purchase common stock totaling 105,849
and 5,280 shares respectively, are not included in the calculation of weighted
average common shares-diluted below as their effect is anti-dilutive.

      The components of basic and diluted income per share are as follows:

                                          3 months ended      3 months ended
                                       September 30, 2002  September 30, 2001

Net income available to common
stockholders                               $ 128,017              98,493
                                            ---------            --------

Common and common equivalent shares outstanding:
     Historical common shares outstanding
     at beginning of period                4,333,095           4,077,290
     Weighted average common shares
     issued during the period                876,227             116,286
                                           ----------            -------

               Weighted average common
               shares--basic               5,209,322            4,193576
     Weighted average common equivalent
     shares issued during the period            -                 35,392
                                          -----------           ---------
                Weighted average common
                shares--diluted            5,209,322           4,228,968

Net income per share--basic and diluted   $     0.02                0.01

4.    INCOME TAXES

A valuation allowance was provided for the income tax benefit of the net
operating losses incurred during the three months ended September 30, 2002
and 2001.


 5.   SEGMENT INFORMATION
The Company has two segments of business: domestic and international operations.
International operations primarily transact sales with customers in the Europe
and continents other than North America, while domestic operations transact
sales primarily in North America. Sales to Chugai, emanating from the United
States, have historically also been included in the domestic business segment.
The Company's formerly active subsidiary, Ho-com, had insignificant revenue for
the three months ended September 30, 2001. Revenue and expenses for Ho-com are
included in the Domestic segment for the three months ended September 30, 2001.
The following table sets forth selected financial data for these segments for
the three-month periods ended September 30, 2002 and 2001.
Three Months Ended September 30

                        Domestic     International           Total

Net sales        2002  $1,131,518       278,522            1,410,040
                 2001  $  841,446       309,616            1,151,062
                     ---------------------------------------------------


Net income(loss) 2002  $   83,568        65,177              148,745
                 2001  $  (26,438)      124,961               98,493
                     ---------------------------------------------------


Depreciation     2002  $   45,904           481               46,385
                 2001  $   90,016            0                90,016
                     ---------------------------------------------------


Interest expense,
 net             2002  $  22,032           8,026              30,058
                 2001  $  28,262           6,590              34,852
                     ---------------------------------------------------

Segment assets   2002 $2,253,089         367,481           2,620,570
                 2001 $2,025,535         303,300           2,328,835
                     ---------------------------------------------------

6.   REDEEMABLE COMMON STOCK


On July 1, 2002, the Company entered into an agreement ("MBL Agreement") with
Medical & Biological Laboratories Co., Ltd. ("MBL"), a strategic partner and
manufacturer of autoimmune diagnostic kits located in Nagoya, Japan, under which
the Company sold 880,282 shares of its $.001 par value common stock to MBL for
gross proceeds of $500,000. Net proceeds to the Company after issuance costs
were $494,793. Under the MBL Agreement, MBL was also granted a put option which
could cause the Company to repurchase, at a future date, the common stock sold
to MBL under the MBL Agreement. Thus, the common stock sold has been designated
"redeemable common stock." The put option requires the stock to be repurchased
at the original purchase price, payable in either a lump-sum purchase or
financed over a six-month period. The put option is exercisable by MBL any time
after the termination or expiration of the distribution agreement between the
Company and RhiGene, MBL's U.S. subsidiary, upon any merger or consolidation of
the Company with another corporation wherein in the Company's stockholders own
less than 50% of the surviving corporation or upon any sale or other disposition
of all or substantially all of the Company's assets. The present distribution
agreement with RhiGene expires on March 31, 2005, though the distribution
agreement may be renewed or extended prior to that time.

Pursuant to the agreement with MBL, as long as MBL holds at least 50% of the
common stock purchased under the MBL agreement, MBL must give its written
consent with respect to the payment of any dividend, the repurchase of any of
the Company's equity securities, the liquidation or dissolution of the Company
or the amendment of any provision of the Company's Articles of Incorporation or
Bylaws which would adversely affect the rights of MBL under the stock purchase
transaction documents. MBL was granted standard anti-dilution rights with
respect to stock issuances not registered under the Securities Act. MBL also
received standard piggyback registration rights along with certain demand
registration rights.

In addition, as part of the MBL Agreement and for no additional consideration,
MBL was issued warrants to purchase an additional 880,282 shares of Common Stock
at a price of $.568 per share, which is equal to an aggregate amount of
$500,000. These warrants expire on July 3, 2007 and may be exercised in whole or
in part at any time prior to their expiration. The estimated fair value of the
warrant upon issuance was calculated as $401,809 using the Black-Scholes model
with the following assumptions: no expected dividend yield, 143% volatility,
risk free interest rate of 4.2% and an expected life of five years. The gross
proceeds of $500,000 were allocated $277,221 to redeemable common stock and
$222,779 to the related warrants based on the relative fair values of the
respective instruments to the fair value of the aggregate transaction. Issuance
costs and the discount attributed to of the warrants upon issuance are being
accreted on the interest method over the 33-month period prior to the presently
expected first date on which the put option may be exercised, which is the
present expiration date of the distribution agreement between the Company and
RhiGene.



































  Item 2.
          CORGENIX MEDICAL CORPORATIONManagement's Discussion and Analysis Of
                 Financial Condition and Results of Operations
                          The following discussion should be read in
conjunction with the consolidated financial statements and accompanying notes
included elsewhere herein.
      General Since the Company's inception, we have been primarily involved in
the research, development, manufacturing and marketing/distribution of
diagnostic tests for sale to clinical laboratories. We currently market 142
products covering autoimmune disorders, vascular diseases, infectious diseases
and liver disease. Our products are sold in the United States, the UK and other
countries through our marketing and sales organization that includes contract
sales representatives, internationally through an extensive distributor network,
and to several significant OEM partners. We manufacture products for inventory
based upon expected sales demand, shipping products to customers, usually within
24 hours of receipt of orders. Accordingly, we do not operate with a customer
order backlog. Except for the fiscal year ended June 30, 1997, we have
experienced revenue growth since our inception, primarily from sales of products
and contract revenues from strategic partners. Contract revenues consist of
licensing fees and milestone payments from research and development agreements
with strategic partners.

      In fiscal year 1996, we began adding third-party OEM licensed products to
our diagnostic product line. Currently we sell 128 products licensed from or
manufactured by third party manufacturers. We expect to expand our relationships
with other companies in the future to gain access to additional products.

      Although we have experienced growth in revenues every year except 1997,
there can be no assurance that, in the future, we will sustain revenue growth,
current revenue levels, or achieve or maintain profitability. Our results of
operations may fluctuate significantly from period-to-period as the result of
several factors, including: (i) whether and when new products are successfully
developed and introduced, (ii) market acceptance of current or new products,
(iii) seasonal customer demand, (iv) whether and when we receive R&D milestone
payments and license fees from strategic partners, (v) changes in reimbursement
policies for the products that we sell, (vi) competitive pressures on average
selling prices for the products that we sell, and (vii) changes in the mix of
products that we sell.

      Critical Accounting Policies

      The Company's consolidated financial statements are prepared in accordance
with accounting principles generally accepted in the United States ("GAAP"). We
believe that the policies identified below are critical to the understanding of
our results of operations. The preparation of financial statements in conformity
with GAAP requires our management to make estimates and assumptions that affect
reported amounts of assets, liabilities, disclosure of contingent assets and
liabilities at the date of the financial statements and reported amounts of
revenues and expenses during the reporting period. Management has made estimates
and assumptions based on these policies. We do not believe that there is a great
likelihood that materially different amounts would be reported if different
assumptions were used. However, the application of these policies involves
judgments and assumptions as to future events and, as a result, actual results
could differ significantly from those estimates.

      Revenue Recognition

      Revenue is recognized upon shipment of products. Provisions are made for
sales discounts and allowances at the time product sales are recognized.

      Inventory Valuation

      Inventories are recorded at the lower of cost or market, using the
first-in, first-out method.

      Allowance for Doubtful Accounts

      The Company maintains an allowance for doubtful accounts based on its
historical experience and provides for any specific collection issues that are
identified. Such allowances have historically been adequate to provide for our
doubtful accounts but involve a significant degree of management judgment and
estimation. Worse than expected future economic conditions, unknown customer
credit problems and other factors may require additional allowances for doubtful
accounts to provided for in future periods.

      Equipment and Software

      Equipment and software are recorded at cost. Equipment under capital
leases is recorded initially at the present value of the minimum lease payments.
Depreciation and amortization is calculated primarily using the straight-line
method over the estimated useful lives of the respective assets which range from
3 to 7 years. The internal and external costs of developing and enhancing
software costs related to website development, other than initial design and
other costs incurred during the preliminary project stage, are capitalized until
the software has been completed. Such capitalized amounts will be amortized
commencing when the website is placed in service on a straight-line basis over a
three-year period. When assets are sold, retired or otherwise disposed of, the
cost and related accumulated depreciation are eliminated from the accounts and a
gain or loss is recognized. Repair and maintenance costs are expensed as
incurred. We evaluate the realizability of our long-lived assets, including
property and equipment, whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable.

      Research and Development and Advertising Costs

      Research and development and advertising costs are expensed when incurred



Results of Operations


      Three Months Ended September 30, 2002 compared to 2001

      Net sales. Net sales for the three months ended September 30, 2002 were
$1,410,040, a 22.5% increase from $1,151,062 in 2001 due to continued expansion
of our worldwide distribution network, overall product mix, and revenue from new
products. Product sales increased in most categories. Domestic sales increased
34.5% while sales to international distributors decreased 10.0%; sales to OEM
partners (other medical companies selling Corgenix manufactured products under
the respective companys' labels) increased 50.3%, primarily due to ordering
patterns and to sales to new OEM partners. Offsetting the above increase in
Domestic sales was a decrease of 20.9% in the sales of Hyaluronic Acid ("HA") to
Chugai for distribution in Japan. Chugai has been and currently is the Company's
largest customer, representing approximately 10.8% and 17% of sales in the
quarters ended September 30, 2002 and 2001, respectively. As noted in our
previous Forms 10-QSB and 10-KSB, Chugai has not forecasted any orders for HA
product after November 2002. As we have not received orders from Chugai after
November 2002, we are internally not projecting any orders by Chugai of HA after
November 2002. The Company expects that the loss of HA sales to Chugai after
November 2002 will eventually be made up via international sales of HA in other
areas of the world. The majority of the Company's sales increase for the current
fiscal quarter was due to higher unit volume (which increased in excess of 45%),
as well as an increase in average price per unit sold of approximately 22.3%,
primarily due to the product mix. Sales of products manufactured for us by other
companies, while still relatively small, are expected to continue to increase
during fiscal 2003.

      Cost of sales. Cost of sales, as a percentage of sales, increased from
27.5% in the first quarter of the prior fiscal year to 29.2% in the current
quarter due primarily to a large increase in lower-margin sales to OEM partners.

      Selling and marketing. Selling and marketing expenses increased 32.6 % to
$309,016 for the three months ended September 30, 2002 from $233,091 in 2001 due
to increases in commissions expense, increased advertising expense, consulting
expense, increased license fees, travel-related expenses associated with various
conventions and trade shows, and payroll-related expense.

      Research and development. Research and development expenses, for the three
months ended September 30, 2002, increased 51.4% to $209,982 from $138,721 for
the three months ended September 30, 2001. Most of this increase came as a
result of increased labor-related costs, travel, purchases of laboratory
supplies associated with joint development projects with a large strategic
partner and development costs of new products.

      General and administrative. General and administrative expenses, for the
three months ended September 30, 2002, increased 2.9% to $300,419 from $292,040
in 2001, due primarily to increases in payroll-related costs in addition to
outside services expense such as legal, accounting and consulting expenses.

      Expenses of the consumer healthcare business. In June 2002, the Company
determined that its consumer healthcare business and associated operations via
consumer websites were not strategic to the company's ongoing objectives and
core medical diagnostic kit business. Accordingly, the Company decided to
abandon and close its internet-based consumer business and all related
e-commerce websites managed and operated by its wholly owned subsidiary,
Health-outfitters.com, Inc. ("ho.com"). The results of Ho.com's operations have
been included in continuing operations in the consolidated statements of
operations for the fiscal quarter ended September 30, 2001. Since some of the
employees and office space of Ho.com have been redeployed into the Company's
core business, only those Ho.com expenses which are not expected to recur are
shown separately in the consolidated statements of operations for the same
quarter ended September 30, 2001. The operating expenses of the consumer
healthcare business not expected to recur were $37,916 during that quarter.
There were no such expenses for the current fiscal quarter. The expenses not
expected to recur consisted primarily of amortization of previously capitalized
software costs and costs associated with advertising and promotion of the
consumer healthcare products. Net sales related to the consumer healthcare
business were $910 during the quarter ended September 30, 2001.

      Interest expense. Interest expense decreased 13.8% to $30,058 in 2002 from
$34,852 in 2001 due primarily to reductions in over-all interest rates.

      Accretion of discount on redeemable common stock. This item represents the
accretion of the discount on redeemable common stock over the 33 month period
from the date the stock was issued to the presently expected first date on which
the related embedded put option may be exercised. The redeemable common stock
was issued in July 2002.

      Net Income to Common Shareholders. This amount represents net income after
the accretion of discount on the redeemable common stock and is the amount used
to calculate net income per common share. Net income to common shareholders
increased from $98,493 to $128,017. Net income per common share increased from
$0.01 to $0.02 per share.

      Liquidity and Capital Resources

      Cash used in operating activities was $122,380 for the current fiscal
quarter compared to $70,666 during the prior fiscal year's comparable quarter.
The cash used in operations for the latest quarter resulted primarily from the
Company's investment in working capital resulting in an increase in accounts
receivable and inventories, offset by a substantial reduction in accounts
payable. The Company believes that uncollectible accounts receivable will not
have a significant effect on future liquidity, as a significant portion of its
accounts receivable are due from enterprises with substantial financial
resources.

      Net cash used by investing activities, the purchase of equipment, was
$13,545 for the current fiscal quarter compared to $2,065 in the prior year's
comparable quarter. The increase was mainly attributable to spending on
internally developed software. No additional related software costs are expected
to be incurred subsequent to September 30, 2002.

      Net cash provided by financing activities amounted to $374,916 for the
current fiscal quarter. This increase in cash provided was primarily due to the
private sale of redeemable common stock as further explained. On July 1, 2002,
the Company entered into an agreement ("MBL Agreement") with Medical &
Biological Laboratories Co., Ltd. ("MBL"), a strategic partner and manufacturer
of autoimmune diagnostic kits located in Nagoya, Japan, under which the Company
sold 880,282 shares of its $.001 par value common stock to MBL for gross
proceeds of $500,000. Net proceeds to the Company after issuance costs were
$494,793. Under the MBL Agreement, MBL was also granted a put option which could
cause the Company to repurchase, at a future date, the common stock sold to MBL
under the MBL Agreement. Thus, the common stock sold has been designated
"redeemable common stock." The put option requires the stock to be repurchased
at the original purchase price, payable in either a lump-sum purchase or
financed over a six-month period. The put option is exercisable by MBL any time
after the termination or expiration of the distribution agreement between the
Company and RhiGene, MBL's U.S. subsidiary, upon any merger or consolidation of
the Company with another corporation wherein in the Company's stockholders own
less than 50% of the surviving corporation or upon any sale or other disposition
of all or substantially all of the Company's assets. The present distribution
agreement with RhiGene expires on March 31, 2005, though the distribution
agreement may be renewed or extended prior to that time.

      Pursuant to the agreement with MBL, as long as MBL holds at least 50% of
the common stock purchased under the MBL agreement, MBL must give its written
consent with respect to the payment of any dividend, the repurchase of any of
the Company's equity securities, the liquidation or dissolution of the Company
or the amendment of any provision of the Company's Articles of Incorporation or
Bylaws which would adversely affect the rights of MBL under the stock purchase
transaction documents. MBL was granted standard anti-dilution rights with
respect to stock issuances not registered under the Securities Act. MBL also
received standard piggyback registration rights along with certain demand
registration rights.

      In addition, as part of the MBL Agreement and for no additional
consideration, MBL was issued warrants to purchase an additional 880,282 shares
of Common Stock at a price of $.568 per share, which is equal to an aggregate
amount of $500,000. These warrants expire on July 3, 2007 and may be exercised
in whole or in part at any time prior to their expiration. The estimated fair
value of the warrant upon issuance was calculated as $401,809 using the
Black-Scholes model with the following assumptions: no expected dividend yield,
143% volatility, risk free interest rate of 4.2% and an expected life of five
years. The gross proceeds of $500,000 were allocated $277,221 to redeemable
common stock and $222,779 to the related warrants based on the relative fair
values of the respective instruments to the fair value of the aggregate
transaction. Issuance costs and the discount attributed to of the warrants upon
issuance are being accreted on the interest method over the 33-month period
prior to the presently expected first date on which the put option may be
exercised, which is the present expiration date of the distribution agreement
between the Company and RhiGene.


      Historically, we have financed our operations primarily through sales of
common and preferred stock. In fiscal 2001, we raised $164,471 before offering
expenses through a private sale of common stock.

      We have also generated cash for operations from sales, in the normal
course of business, of diagnostic products and agreements with strategic
partners. As of September 30, 2002, our accounts payable decreased 46.9% to
$294,145 from $553,505 as of June 30, 2002 due to a concerted effort to bring
our accounts payable more current. Although sales increased 22.5% for the
current fiscal quarter compared to the same quarter in the prior year, net
accounts receivable only increased 5.7% to $734,096 as of September 30, 2002
from $694,394 as of June 30, 2002, primarily because of relatively more timely
payment by our customers.

      Our future capital requirements will depend on a number of factors,
including the rate at which we grow our business and our investment in
proprietary research activities, the ability of our current and future strategic
partners to fund outside research and development activities, our success in
increasing sales of both existing and new products and collaborations, expenses
associated with unforeseen litigation, regulatory changes, competition,
technological developments, general economic conditions and potential future
merger and acquisition activity. Our principal sources of liquidity have been
cash provided from operating and financing activities, cash raised from the
private sale of common stock mentioned above, and long-term debt financing, of
which $577,798 remained outstanding as of September 30, 2002. We believe that we
will continue investigating new debt agreements and may sell additional equity
securities in fiscal year 2003 to develop the markets and obtain the regulatory
approvals for the HA products, and to pursue all of our strategic objectives. We
believe that our existing cash, cash and working capital and anticipated cash
flow from existing operations will be sufficient to support our current
operating plan for at least the next 12 months. This estimate of our future
capital requirements is a forward-looking statement that is based on assumptions
that may prove to be wrong and that involve varying risks and uncertainties.

                                       Item 3.

                               Controls and Procedures

Evaluation of disclosure controls and procedures. The Company, under the
supervision and with the participation of the Company's management, including
its Chief Executive Officer and Chief Financial Officer, carried out an
evaluation of the effectiveness of the design and operation of the Company's
disclosure controls and procedures (as defined in Rules 240.13a-14(c) and
15d-14(c) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of
a date within ninety days before the filing date of this quarterly report (the
"Evaluation Date"). Based upon this evaluation, the Chief Executive Officer and
Chief Financial Officer concluded that, as of the Evaluation Date, the Company's
disclosure controls and procedures were effective for the purposes of recording,
processing, summarizing and timely reporting information required to be
disclosed by the Company in the reports that it files under the Securities
Exchange Act of 1934 and that such information is accumulated and communicated
to the Company's management in order to allow timely decisions regarding
required disclosure.

Changes in internal controls. There have been no significant changes in the
Company's internal controls or in other factors that could significantly affect
the Company's disclosure controls and procedures subsequent to the Evaluation
Date, nor were there any significant deficiencies or material weaknesses in the
Company's internal controls.

      Forward-Looking Statements and Risk Factors

      This 10-QSB includes statements that are not purely historical and are
"forward-looking statements" within the meaning of Section 21E of the Securities
Act of 1934, as amended, including statements regarding our expectations,
beliefs, intentions or strategies regarding the future. All statements other
than historical fact contained in this 10-QSB, including, without limitation,
statements regarding future product developments, acquisition strategies,
strategic partnership expectations, technological developments, the development,
launch and operation of health-outfitters.com, the availability of necessary
components, research and development programs and distribution plans, are
forward-looking statements. All forward-looking statements included in this
10-QSB are based on information available to us on the date hereof, and we
assume no obligation to update such forward-looking statements. Although we
believe that the assumptions and expectations reflected in such forward-looking
statements are reasonable, we can give no assurance that such expectations will
prove to have been correct or that we will take any actions that may presently
be planned.

      Certain factors that could cause actual results to differ materially from
those expected include the following:

      Losses   Incurred;   Future   Capital   Needs;   Risks  Relating  to  the
Professional Products Business; Uncertainty of Additional Funding

      We have incurred operating losses and negative cash flow from operations
for most of our history. Losses incurred since our inception have aggregated
$4,124,762, and there can be no assurance that we will be able to generate
positive cash flows to fund our operations in the future or to pursue our
strategic objectives. Assuming no significant uses of cash in acquisition
activities or other significant changes, we believe that we will have sufficient
cash to satisfy our needs for at least the next year. If we are not able to
operate profitably and generate positive cash flows sufficient for both the
diagnostic business and the consumer products business, we may need to raise
additional capital to fund our operations. If we need additional financing to
meet our requirements, there can be no assurance that we will be able to obtain
such financing on terms satisfactory to us, if at all. Alternatively, any
additional equity financing may be dilutive to existing stockholders, and debt
financing, if available, may include restrictive covenants. If adequate funds
are not available, we might be required to limit our research and development
activities or our selling and marketing activities any of which could have a
material adverse effect on the future of the business.

      Dependence on Collaborative  Relationships  and Third Parties for Product
      Development and Commercialization

      We have historically entered into licensing and research and development
agreements with collaborative partners, from which we derived a significant
percentage of our revenues in past years. Pursuant to these agreements, our
collaborative partners have specific responsibilities for the costs of
development, promotion, regulatory approval and/or sale of our products. We will
continue to rely on future collaborative partners for the development of
products and technologies. There can be no assurance that we will be able to
negotiate such collaborative arrangements on acceptable terms, if at all, or
that current or future collaborative arrangements will be successful. To the
extent that we are not able to establish such arrangements, we could experience
increased capital requirements or be forced to undertake such activities at our
own expense. The amount and timing of resources that any of these partners
devotes to these activities will generally be based on progress by us in our
product development efforts. Usually, collaborative arrangements may be
terminated by the partner upon prior notice without cause and there can be no
assurance that any of these partners will perform its contractual obligations or
that it will not terminate its agreement. With respect to any products
manufactured by third parties, there can be no assurance that any third-party
manufacturer will perform acceptably or that failures by third parties will not
delay clinical trials or the submission of products for regulatory approval or
impair our ability to deliver products on a timely basis.

      Uncertainty  as to Future  Orders for  Hyaluronic  Acid Test Kits  ("HA")
from Company's Largest Customer

      Chugai has unexpectedly not forecast any orders for HA after November
2002. Our management has not determined Chugai's intent with respect to orders
of HA after November 2002 and we are trying to determine the status of these
orders. As we are unclear whether or not Chugai will place orders after November
2002, we are internally not projecting any orders by Chugai of HA after November
2002.

      No Assurance of Successful or Timely Development of Additional Products

      Our business strategy includes the development of additional diagnostic
products both for the diagnostic business and consumer products business. Our
success in developing new products will depend on our ability to achieve
scientific and technological advances and to translate these advances into
commercially competitive products on a timely basis. Development of new products
requires significant research, development and testing efforts. We have limited
resources to devote to the development of products and, consequently, a delay in
the development of one product or the use of resources for product development
efforts that prove unsuccessful may delay or jeopardize the development of other
products. Any delay in the development, introduction and marketing of future
products could result in such products being marketed at a time when their cost
and performance characteristics would not enable them to compete effectively in
their respective markets. If we are unable, for technological or other reasons,
to complete the development and introduction of any new product or if any new
product is not approved or cleared for marketing or does not achieve a
significant level of market acceptance, our results of operations could be
materially and adversely affected.

      Competition in the Diagnostics Industry

      Competition in the human medical diagnostics industry is, and is expected
to remain, significant. Our competitors range from development stage diagnostics
companies to major domestic and international pharmaceutical companies. Many of
these companies have financial, technical, marketing, sales, manufacturing,
distribution and other resources significantly greater than ours. In addition,
many of these companies have name recognition, established positions in the
market and long standing relationships with customers and distributors.
Moreover, the diagnostics industry has recently experienced a period of
consolidation, during which many of the large domestic and international
pharmaceutical companies have been acquiring mid-sized diagnostics companies,
further increasing the concentration of resources. There can be no assurance
that technologies will not be introduced that could be directly competitive with
or superior to our technologies.

           Governmental Regulation of Diagnostics Products

      The testing, manufacture and sale of our products is subject to regulation
by numerous governmental authorities, principally the FDA and certain foreign
regulatory agencies. Pursuant to the Federal Food, Drug, and Cosmetic Act, and
the regulations promulgated there under, the FDA regulates the preclinical and
clinical testing, manufacture, labeling, distribution and promotion of medical
devices. We are not able to commence marketing or commercial sales in the United
States of new products under development until we receive clearance from the
FDA. The testing for, preparation of and subsequent FDA regulatory review of
required filings can be a lengthy, expensive and uncertain process.
Noncompliance with applicable requirements can result in, among other
consequences, fines, injunctions, civil penalties, recall or seizure of
products, repair, replacement or refund of the cost of products, total or
partial suspension of production, failure of the government to grant premarket
clearance or pre-market approval for devices, withdrawal of marketing clearances
or approvals, and criminal prosecution.

      There can be no assurance that we will be able to obtain necessary
regulatory approvals or clearances for our products on a timely basis, if at
all, and delays in receipt of or failure to receive such approvals or
clearances, the loss of previously received approvals or clearances, limitations
on intended use imposed as a condition of such approvals or clearances or
failure to comply with existing or future regulatory requirements could have a
material adverse effect on our business.

      Dependence on Distribution  Partners for Sales of Diagnostic  Products in
International Markets

      We have entered into distribution agreements with collaborative partners
in which we have granted distribution rights for certain of our products to
these partners within specific international geographic areas. Pursuant to these
agreements, our collaborative partners have certain responsibilities for market
development, promotion, and sales of the products. If any of these partners
fails to perform its contractual obligations or terminates its agreement, this
could have a material adverse effect on our business, financial condition and
results of operations.

      Governmental Regulation of Manufacturing and Other Activities

      As a manufacturer of medical devices for marketing in the United States,
we are required to adhere to applicable regulations setting forth detailed good
manufacturing practice requirements, which include testing, control and
documentation requirements. We must also comply with Medical Device Report
("MDR") requirements, which require that a manufacturer report to the FDA any
incident in which its product may have caused or contributed to a death or
serious injury, or in which its product malfunctioned and, if the malfunction
were to recur, it would be likely to cause or contribute to a death or serious
injury. We are also subject to routine inspection by the FDA for compliance with
QSR requirements, MDR requirements and other applicable regulations. The FDA has
recently implemented new QSR requirements, including the addition of design
controls that will likely increase the cost of compliance. Labeling and
promotional activities are subject to scrutiny by the FDA and, in certain
circumstances, by the Federal Trade Commission. We may incur significant costs
to comply with laws and regulations in the future, which may have a material
adverse effect upon our business, financial condition and results of operations.

      Regulation Related to Foreign Markets

      Distribution of diagnostic products outside the United States is subject
to extensive government regulation. These regulations, including the
requirements for approvals or clearance to market, the time required for
regulatory review and the sanctions imposed for violations, vary from country to
country. We may be required to incur significant costs in obtaining or
maintaining foreign regulatory approvals. In addition, the export of certain of
our products that have not yet been cleared for domestic commercial distribution
may be subject to FDA export restrictions. Failure to obtain necessary
regulatory approval or the failure to comply with regulatory requirements could
have a material adverse effect on our business, financial condition and results
of operations.


      Uncertain  Availability  of  Third  Party  Reimbursement  for  Diagnostic
      Products

      In the United States, health care providers that purchase diagnostic
products, such as hospitals and physicians, generally rely on third party
payers, principally private health insurance plans, federal Medicare and state
Medicaid, to reimburse all or part of the cost of the procedure. Third party
payers are increasingly scrutinizing and challenging the prices charged for
medical products and services and they can affect the pricing or the relative
attractiveness of the product. Decreases in reimbursement amounts for tests
performed using our diagnostic products, failure by physicians and other users
to obtain reimbursement from third party payers, or changes in government and
private third party payers' policies regarding reimbursement of tests utilizing
diagnostic products, may affect our ability to sell our diagnostic products
profitably. Market acceptance of our products in international markets is also
dependent, in part, upon the availability of reimbursement within prevailing
health care payment systems.

      Uncertainty of Protection of Patents, Trade Secrets and Trademarks

      Our success depends, in part, on our ability to obtain patents and license
patent rights, to maintain trade secret protection and to operate without
infringing on the proprietary rights of others. There can be no assurance that
our issued patents will afford meaningful protection against a competitor, or
that patents issued to us will not be infringed upon or designed around by
others, or that others will not obtain patents that we would need to license or
design around. We could incur substantial costs in defending the Company or our
licensees in litigation brought by others. Our business could be adversely
affected.

      Risks Regarding Potential Future Acquisitions

      Our growth strategy includes the desire to acquire complementary
companies, products or technologies. There is no assurance that we will be able
to identify appropriate companies or technologies to be acquired, to negotiate
satisfactory terms for such an acquisition, or to obtain sufficient capital to
make such acquisitions. Moreover, because of limited cash resources, we will be
unable to acquire any significant companies or technologies for cash and our
ability to effect acquisitions in exchange for our capital stock may depend upon
the market prices for our Common Stock. If we do complete one or more
acquisitions, a number of risks arise, such as short-term negative effects on
our reported operating results, diversion of management's attention,
unanticipated problems or legal liabilities, and difficulties in the integration
of potentially dissimilar operations. The occurrence of some or all of these
risks could have a material adverse effect on our business, financial condition
and results of operations.

      Dependence on Suppliers

      The components of our products include chemical and packaging supplies
that are generally available from several suppliers, except certain antibodies,
which we purchases from single suppliers. We mitigate the risk of a loss of
supply by maintaining a sufficient supply of such antibodies to ensure an
uninterrupted supply for at least three months. We have also qualified second
vendors for all critical raw materials and believe that we can substitute a new
supplier with respect to any of these components in a timely manner. However,
there can be no assurances that we will be able to substitute a new supplier in
a timely manner and failure to do so could have a material adverse effect on our
business, financial condition and results of operations.

      Limited Manufacturing Experience with Certain Products

      Although we have manufactured over twelve million diagnostic tests based
on our proprietary applications of ELISA (enzyme linked immuno-absorbent assay)
technology, certain of our diagnostic products in consideration for future
development, incorporate technologies with which we have little manufacturing
experience. Assuming successful development and receipt of required regulatory
approvals, significant work may be required to scale up production for each new
product prior to such product's commercialization. There can be no assurance
that such work can be completed in a timely manner and that such new products
can be manufactured cost-effectively, to regulatory standards or in sufficient
volume.

      Seasonality of Products; Quarterly Fluctuations in Results of Operations

      Our revenue and operating results have historically been minimally subject
to quarterly fluctuations. There can be no assurance that such seasonality in
our results of operations will not have a material adverse effect on our
business.

      Dependence on Key Personnel

      Because of the specialized nature of our business, our success will be
highly dependent upon our ability to attract and retain qualified scientific and
executive personnel. In particular, we believe our success will depend to a
significant extent on the efforts and abilities of Dr. Luis R. Lopez and
Douglass T. Simpson, who would be difficult to replace. There can be no
assurance that we will be successful in attracting and retaining such skilled
personnel, who are generally in high demand by other companies. The loss of,
inability to attract, or poor performance by key scientific and executive
personnel may have a material adverse effect on our business, financial
condition and results of operations.

      Product Liability Exposure and Limited Insurance

      The testing, manufacturing and marketing of medical diagnostic devices
entails an inherent risk of product liability claims. To date, we have
experienced no product liability claims, but any such claims arising in the
future could have a material adverse effect on our business, financial condition
and results of operations. Our product liability insurance coverage is currently
limited to $2 million. Potential product liability claims may exceed the amount
of our insurance coverage or may be excluded from coverage under the terms of
our policy or limited by other claims under our umbrella insurance policy.
Additionally, there can be no assurance that our existing insurance can be
renewed by us at a cost and level of coverage comparable to that presently in
effect, if at all. In the event that we are held liable for a claim against
which we are not insured or for damages exceeding the limits of our insurance
coverage, such claim could have a material adverse effect on our business,
financial condition and results of operations.

      Limited Public Market;  Possible Volatility in Stock Prices;  Penny Stock
      Rules

      There has, to date, been no active public market for our Common Stock, and
there can be no assurance that an active public market will develop or be
sustained. Although our Common Stock has been traded on the OTC Bulletin
Board(R) since February 1998, the trading has been sporadic with insignificant
volume.

      Moreover, the over-the-counter markets for securities of very small
companies historically have experienced extreme price and volume fluctuations
during certain periods. These broad market fluctuations and other factors, such
as new product developments and trends in our industry and the investment
markets and economic conditions generally, as well as quarterly variation in our
results of operations, may adversely affect the market price of our Common
Stock. In addition, our Common Stock is subject to rules adopted by the
Securities and Exchange Commission regulating broker-dealer practices in
connection with transactions in "penny stocks." As a result, many brokers are
unwilling to engage in transactions in our Common Stock because of the added
disclosure requirements.

      Risks Associated with Exchange Rates

      Our financial statements are presented in US dollars. At the end of each
fiscal quarter and the fiscal year, we convert the financial statements of
Corgenix UK, which operates in pounds sterling, into US dollars, and consolidate
them with results from Corgenix, Inc. We may, from time to time, also need to
exchange currency from income generated by Corgenix UK. Foreign exchange rates
are volatile and can change in an unknown and unpredictable fashion. Should the
foreign exchange rates change to levels different than anticipated by us, our
business, financial condition and results of operations may be materially
adversely affected.
                          CORGENIX MEDICAL CORPORATION


                                     PART II


                                Other Information





Item 1.    Legal Proceedings


      Corgenix is not a party to any material litigation or legal proceedings.


Item 2.    Changes in Securities and Use of Proceeds


                From July 1, 2001 through June 30, 2002, we sold a total of
237,300 shares of Common Stock at $.8722 per share for a total of $208,159 to 12
accredited investors and one foreign investor. The sales were made in reliance
upon the exemption from the registration requirements of the Securities Act of
1933, as amended, provided by Section 4 (2) of the Securities Act. In addition,
on July 1, 2002, we sold a total of 880,282 shares of redeemable common stock at
$.568 per share for a total of $500,000 to Medical & Biological laboratories
Co., Ltd. (MBL), a Japanese strategic investor (see note 6). None of the above
shares were registered under federal or state securities laws, and, therefore,
will be "restricted securities" as such term is defined in Rule 144 promulgated
under the Securities Act. The Company intends to use the proceeds of the private
placement to assist in the market and regulatory development of the Company's HA
diagnostic test, acquire capital equipment, reduce short-term debt, accelerate
research and development of new products and for general working capital.



Item 3.    Defaults Upon Senior Securities


      None


Item 4.    Submission of Matters to a Vote of Security Holders


The Registrant's annual meeting of stockholders will be held on December 11,
2002. No matters were submitted to a vote of the Company's security holders
during the period covered by this report.

Item 5.    Other Information


      None

Item 6.  Exhibits and Reports on Form 8-K.

a.    Index to and Description of Exhibits













Exhibit
Number   Description of Exhibit

2.1      Agreement  and Plan of Merger  dated as of May 12,  1998 by
         and  among  Gray  Wolf   Technologies,   Inc.,   Gray  Wolf
         Acquisition Corp. and REAADS Medical Products,  Inc. (filed
         as Exhibit 2.1 to the Company's  Registration  Statement on
         Form 10-SB filed June 29, 1998, and incorporated  herein by
         reference).
2.2      First Amendment to Agreement and Plan of Merger dated as
         of May 22, 1998 by and among Gray Wolf Technologies, Inc.,
         Gray Wolf Acquisition Corp. and REAADS Medical Products,
         Inc. (filed as Exhibit 2.2 to the Company's Registration
         Statement on Form 10-SB filed June 29, 1998, and
         incorporated herein by reference).
2.3      Second Amendment to Agreement and Plan of Merger dated as of June 17,
         1998 by and among the Company and TransGlobal Financial Corporation
         (filed as Exhibit 2.3 to the Company's Registration Statement on Form
         10-SB filed June 29, 1998, and incorporated herein by reference).
3.1      Articles of Incorporation, as amended (filed as Exhibit 3.1 to the
         Company's Registration Statement on Form 10-SB filed June 29, 1998, and
         incorporated herein by reference).
3.2      Bylaws (filed as Exhibit 3.2 to the Company's Registration Statement on
         Form 10-SB filed June 29, 1998, and incorporated herein by reference.

3.3      Articles of Incorporation of health-outfitters.com, Inc.
         dated November 16, 1999 (filed as Exhibit 3.3 to the
         Company's filing on Form 10-QSB for the fiscal quarter
         ended December 31, 1999).

3.4      Bylaws of health-outfitters.com, Inc. dated November 16,
         1999 (filed as Exhibit 3.4 to the Company's filing on Form
         10-QSB for the fiscal quarter ended December 31, 1999).

10.1     Manufacturing Agreement dated September 1, 1994 between
         Chugai Pharmaceutical Co., Ltd. and REAADS Medical
         Products, Inc. (filed as Exhibit 10.1 to the Company's
         Registration Statement on Form 10-SB filed June 29, 1998,
         and incorporated herein by reference).

10.2     Amendment to the Manufacturing Agreement dated as of
         January 17, 1995 between Chugai Pharmaceutical Co., Ltd.
         and REAADS Medical Products, Inc. (filed as Exhibit 10.2
         to the Company's Registration Statement on Form 10-SB
         filed June 29, 1998, and incorporated herein by reference).
10.3     Amendment to Agreement dated November 17, 1997 between
         Chugai Diagnostic Science, Co., Ltd. and REAADS Medical
         Products, Inc. (filed as Exhibit 10.3 to the Company's
         Registration Statement on Form 10-SB filed June 29, 1998,
         and incorporated herein by reference).
10.4     License Agreement dated June 30, 2001 between Chugai
         Diagnostic Science Co., Ltd. and Corgenix Medical
         Corporation.

10.9     Office Lease dated May 5, 2001 between Crossroads West LLC/Decook
         Metrotech LLC and Corgenix, Inc.
10.10    Guarantee dated November 1, 1997 between William George Fleming,
         Douglass Simpson and Geoffrey Vernon Callen (filed as Exhibit 10.10 to
         the Company's Registration Statement on Form 10-SB filed June 29, 1998,
         and incorporated herein by reference).
10.11    Employment Agreement dated April 1, 2001 between Luis R.
         Lopez and the Company.

10.12    Employment Agreement dated April 1, 2001 between Douglass
         T. Simpson and the Company.
10.13    Employment Agreement dated April 1, 2001 between Ann L.
         Steinbarger and the Company.
10.14    Employment Agreement dated April 1, 2001 between Taryn G.
         Reynolds and the Company.
10.15    Employment Agreement dated April 1, 2001 between Catherine (O'Sullivan)
         Fink and the Company.
10.16    Consulting Contract dated May 22, 1998 between Wm. George
         Fleming, Bond Bio-Tech, Ltd. and the Company (filed as
         Exhibit 10.16 to the Company's Registration Statement on
         Form 10-SB filed June 29, 1998, and incorporated herein by
         reference).
10.17    Stock Purchase Agreement dated September 1, 1993 between
         Chugai Pharmaceutical Co., Ltd. and REAADS Medical
         Products, Inc. (filed as Exhibit 10.17 to the Company's
         Registration Statement on Form 10-SB filed June 29, 1998,
         and incorporated herein by reference).
10.19    Note dated January 6, 1997 between REAADS Medical Products, Inc. and
         Eagle Bank (filed as Exhibit 10.19 to the Company's Registration
         Statement on Form 10-SB filed June 29, 1998, and incorporated herein by
         reference).
10.24    Form of Indemnification Agreement between the Company and its directors
         and officers (filed as Exhibit 10.24 to the Company's Registration
         Statement on Form 10-SB/A-1 filed September 24, 1998 and incorporated
         herein by reference).
10.27    Warrant agreement dated June 1, 2000 between the Company
         and Taryn G. Reynolds.
10.30    Employment Agreement dated March 1, 2001 between William H. Critchfield
         and the Company (filed as Exhibit 10.30 to the Company's filing on Form
         10-QSB for the fiscal quarter ended March 31, 2001).
10.31    Business Development and Consulting Agreement dated August
         27, 2002 between Ascendiant Capital Group, Inc. and the
         Company.
10.32*   Consulting Agreement dated September 29, 2002 between Eiji Matsuura,
         Ph.D and the Company.
10.33*   License Agreement dated September 29, 2002 between Eiji Matsuura, Ph.D
         and the Company.
21.1     Amended Subsidiaries of the Registrant (filed as Exhibit 21.1 to the
         Company's Registration Statement on Form 10-SB filed June 29, 1998).
21.2     Promissory note dated October 1, 2001 between W.G. Fleming
         and Corgenix UK, Ltd.
21.3     Promissory note dated October 1, 2001 between W.G. Fleming
         and Corgenix UK, Ltd.
21.4     Warrant Agreement dated October 11, 2001 between Phillips
         V. Bradford and the Company.
21.5     Warrant Agreement dated October 11, 2001 between Charles
         F. Ferris and the Company.
21.6     Underlease Agreement dated October 3, 2001 between G.V.
         Callen, A.G. Pirmohamed and Corgenix UK, Ltd.
21.7     Distribution Agreement and OEM Agreement dated March 14,
         2002 between RhiGene, Inc. and the Company.
21.8     Distribution and OEM Agreement dated March 14, 2002 dated
         March 14, 2002 between RhiGene, Inc., and the Company.
21.9     Warrant Agreement dated March 15,2002 between the Liolios
         Group, Inc. and the Company.
23.1*    Certificate of Corgenix Medical Corporation's Chief Executive Officer
         and Chief Financial Officer pursuant to section 906 of the
         Sarbanes-Oxley Act of 2002.

*   Filed herewith.
----------------------------------------
      (b)  Reports on Form 8-K.

           None


<PAGE>


                              CONSULTING AGREEMENT


This  Agreement is made  effective as of September 29, 2002,  between  Corgenix
Medical Corporation,  ("Corgenix) and Eiji Matsuura,  Ph.D. ("Dr. Matsuura") of
Okayama University.

      1. Background.  Corgenix desires to engage Dr. Matsuura as an independent
         ----------
contractor  to provide  such  advice,  consultation,  and other  technical  and
scientific  assistance to Corgenix as may from time to time be requested.  This
Agreement sets forth the terms and conditions for such services.

      2. Services.  Dr.  Matsuura will be engaged as an independent  contractor
         --------
to  provide  such  services  as  are   reasonably   requested  by  Corgenix  in
connection   with  the   development  of  diagnostic   tests  relating  to  the
determination of oxidized lipoproteins and related analytes or antibodies.

      3.  Compensation.  During the term of this  Agreement,  Dr. Matsuura will
          ------------
receive the following compensation for services.

(a)   A fee of $50,000, paid as follows:

i) $15,000 upon the execution of the Agreement, ii) $15,000 six months after the
date first written above, iii) $10,000 twelve months after the date first
written above, and iv) $10,000 eighteen months after the date first written
above.

(b)   Reimbursement for reasonable business expenses actually incurred in the
      performance of consulting services, such expenses to be approved by
      Corgenix in advance.

      4. Independent Contractor. In the performance of the consulting services,
Dr. Matsuura shall be deemed to be an independent contractor (and not an
employee or agent of Corgenix) for all purposes under any and all laws, whether
existing or future, including without limitation Social Security laws,
unemployment insurance laws, and withholding and other employment taxation laws
of the United States and Japan. Dr. Matsuura agrees to comply with applicable
laws, rules, and regulations in respect to independent contractors, including
without limitation, the payment of all taxes required.

      5. Prior Obligation or Restriction. Both parties warrant and agree that
there is no obligation or restriction and neither will assume any obligation or
restriction that would in any way interfere or be inconsistent with its duties
and/or responsibilities under this Agreement.

      6. Confidential Information. Dr. Matsuura shall not, at any time during or
following the work on behalf of Corgenix, directly or indirectly distribute,
use, or disclose to any person other than authorized officers or personnel of
Corgenix, trade secret or confidential information relating to any activity of
Corgenix (hereafter "Confidential Information"). All notes, memoranda, or other
writings made by Dr. Matsuura or which may come into Dr. Matsuura's possession
while working with Corgenix, or which relate in any way to or embody any
Confidential Information concerning any activity of Corgenix marketing and
business ideas, shall be the exclusive property of Corgenix and shall be kept on
the Corgenix premises except when required elsewhere in connection with its
activities. Upon completion of Dr. Matsuura's services, Dr. Matsuura will
deliver to the Company all physical materials in its possession or within its
control relating to any Confidential Information which belongs to Corgenix. Dr.
Matsuura shall execute all such documents of assignment or other documents as
Corgenix may deem reasonably required to effect the provisions of this Paragraph
6. The provisions of this Paragraph 6 shall survive the termination of this
Agreement.

      7. Term.  The term of this  Agreement  shall  commence on the date hereof
         ----
and continue for twenty-four (24) months.

      8.  Miscellaneous.  This  Agreement  shall be governed by the laws of the
          -------------
state of Colorado,  USA. If any term or  provision  of this  Agreement is found
by a court of  competent  jurisdiction  to be illegal or invalid for any reason
whatsoever,  such  illegality  or  invalidity  shall not affect the validity of
the remainder hereof.


IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
day and year first above written.

      Corgenix Medical Corporation                       Eiji Matsuura, Ph.D.

sign: s/ Luis R. Lopez, MD                     sign:s/ Eiji Matsuura, Ph.D.

name: Luis R. Lopez, MD                        name:Eiji Matsuura, Ph.D.

                                   title: CEO

<PAGE>


                                LICENSE AGREEMENT


This agreement (the "License Agreement") is made as of the 29 day of September,
2002, by and between Corgenix Medical Corporation, a Nevada corporation, having
its principal office at 12061 Tejon Street, Westminster, Colorado 80234, U.S.A.
("Corgenix") and Eiji Matsuura, Ph.D. ("Dr. Matsuura"), an individual having his
place of residence at **************, Japan.

                                   WITNESSETH:

WHEREAS, Dr. Matsuura is the owner of all right, title and interest in and to
certain Technology (as hereinafter defined) relating to methods for the
determination of oxidized lipoproteins and related analytes or antibodies,
including certain Patents (as hereinafter defined); and

WHEREAS, Corgenix is engaged in the business of developing, manufacturing,
selling and distributing diagnostic tests, instrumentation and related products,
and desires to obtain a license from Dr. Matsuura in order to make, use, sell
and distribute diagnostic products ("Licensed Product") using the Technology on
its own behalf; and

WHEREAS, Dr. Matsuura is willing to grant Corgenix a license under the Patents
to make, use, sell and distribute Licensed Product subject to the terms and
conditions set out herein.

NOW, THEREFORE, in consideration of the mutual covenants and agreements
contained herein, the parties hereto agree as follows:

ARTICLE 1 (DEFINITIONS)
   In this License Agreement, the following words and expressions have the
   following meanings: 1.1 "Effective Date" means the date first above written.
   1.2 "Licensed Product" means human diagnostic products to be developed,
   manufactured and sold by Corgenix under the Patents. 1.3 "Net Sales" means
   the total invoice price charged by Corgenix and/or Subsidiaries to
   non-Subsidiary third parties for the sale of the Licensed Product, less
   returns, freight charges, insurance premium and customary trade discounts
   actually taken, consumption tax or other taxes levied and customs duties.
   1.4  "Party" means Corgenix or Dr. Matsuura; "Parties" means Corgenix and
   Dr. Matsuura.
1.5 "Patents" means US Patent No. 5,900,359 issued on May 4, 1999, attached
   hereto as Exhibit A, and any subsequent patents issued to either or both of
   the Parties relating to the Technology.
1.6   "Japanese Patents" means the following patent applications: Japanese
   Patent Application No. 07-510213: Method for determination of oxidized
   lipoproteins and use thereof"; Japanese Patent Application No.
   PCT/JP02/00723: "Ligand for beta-2-glycoprotein I and use thereof";
   Japanese Patent Application No. 2002-261366: "Method for measuring oxidized
   LDL-beta-2-glycoprotein I complex in living body" attached hereto as
   Exhibit B; and any subsequent patents issued to either or both of the
   Parties relating to the Technology.
1.7 "Technology" means all information in the possession of Dr. Matsuura
   regarding methods for the determination of oxidized lipoproteins and related
   analytes or antibodies as related to the Patents or the Japanese Patents.
   1.8 "Subsidiary" means companies that are controlled by Corgenix as of the
   Effective Date. For the purpose of this definition, "control" shall mean
   direct beneficial ownership of greater than fifty percent (50%) of the voting
   stock or other equity ownership interest of such company. 1.9 "Territory"
   means worldwide except Japan.
   1.10 "Consulting Agreement" shall mean an agreement for consulting services
   between Corgenix and Dr. Matsuura dated September 29, 2002 attached hereto as
   Exhibit C.

ARTICLE 2 (GRANT OF LICENSE)
   Dr. Matsuura hereby grants to Corgenix exclusive license to manufacture, use,
   promote to sell, and sell the Licensed Product relating to the Patents in the
   Territory during the term of this License Agreement. Corgenix shall not
   sublicense the said right to any third parties without prior written consent
   of Dr. Matsuura which consent shall not be unreasonably withheld by Dr.
   Matsuura, provided, however, that Corgenix may further sublicense the said
   right to Subsidiaries without the said consent of Dr. Matsuura.

ARTICLE 3 (PATENTS AND JAPANESE PATENTS)
3.1   Patents.
3.1.1 Corgenix is responsible for the maintenance and prosecution of all
           Patents outside of Japan.
3.1.2 Corgenix shall be responsible for the translation of the Japanese
           Patents into English and the filing of US patents which shall be
           assigned to Corgenix and Dr. Matsuura.
3.1.3 Should Corgenix decide not to prosecute or maintain any or all of the
           Patents, the Patent(s) so affected shall be reassigned by Corgenix
           to Dr. Matsuura.
3.2   Japanese Patents. Dr. Matsuura is responsible for the maintenance and
   prosecution of all Japanese Patents. Should Dr. Matsuura decide for any
   reason not to maintain any or all of the Japanese Patents, he shall
   immediately notify Corgenix.

ARTICLE 4 (REGULATORY APPROVAL)
   Corgenix shall be responsible for, and shall bear the expenses of, filing and
   prosecuting any application to obtain the required governmental approvals or
   consents necessary to manufacture and market the Licensed Product in the
   Territory.

ARTICLE 5 (TECHNICAL ASSISTANCE)
   Both Parties agree to collaborate on the Technology and to provide ongoing
   technical support concerning the Patents in order to obtain the governmental
   approvals or consents necessary to develop, manufacture and market the
   Licensed Product, and effectively promote the Licensed Product in the
   Territory.

ARTICLE 6 (ROYALTIES AND PAYMENTS)
   6.1 In consideration of the grant of the rights by Dr. Matsuura to Corgenix
   under this License Agreement, Corgenix shall pay to Dr. Matsuura as follows:
   a royalty of four (4) percent (4 %) of Net Sales of the Licensed Product sold
   by Corgenix and its Subsidiaries for each calendar half year commencing on
   the Effective Date and thereafter during the term of this License Agreement
   shall be paid to Dr. Matsuura semiannually within forty-five (45) days after
   the ends of every June and December.

   6.2     Payment Method. All payments to Dr. Matsuura under this License
   Agreement, except as otherwise agreed, shall be remitted in United States
   Dollars by telegraphic transfer to the account of Dr. Matsuura, at a bank
   designated by Dr. Matsuura. If a payment is delayed, overdue interest rate
   will be the US Dollar London Interbank Offered Rate of corresponding
   overdue period plus three percent (3%) per annum.

   6.3 Concurrent with the signing of the License Agreement, the parties shall
   execute a Consulting Agreement whereby Dr. Matsuura will provide certain
   consulting services to Corgenix.

ARTICLE 7 (RECORDS)
   Corgenix shall keep complete and accurate records and books in sufficiently
   detailed to show the amount of the Licensed Products manufactured and sold,
   and the running royalty due and payable to Dr. Matsuura for five (5) years
   from each calendar year. Corgenix shall, at the request and at the expense of
   Dr. Matsuura, permit Dr. Matsuura or an independent accountant designated by
   Dr. Matsuura to have access to such records to examine and to copy, during
   ordinary business hours, as may be necessary to verify or determine any
   royalties, paid or payable, under this License Agreement.

                           ARTICLE 8 (IMPROVEMENTS)
   The Parties acknowledge and agree that certain inventions and improvements
   (collectively, "Improvements") may be made by either Party through the use of
   the Patents. Each Party shall inform the other Party of any Improvements.

ARTICLE 9 (CONFIDENTIALITY)
   Each Party acknowledges that during the course of this License Agreement it
   will become privy to confidential information of the other Party including
   technology, business strategy and other technical, business and financial
   matters. Each Party further acknowledges that the disclosure of such
   information to a third party, or the use of such information for purposes
   other than the purposes of this License Agreement, would cause irreparable
   injury to the other Party, which injury might not be compensated for
   adequately by money damages. Each Party accordingly agrees, during the term
   of this License Agreement and five (5) years thereafter, to hold all
   information provided by the other Party in strict confidence and not to
   disclose any such information to a third party except as expressly permitted
   by the other Party, or use such information for any purpose other than the
   purposes hereof.

   As used herein, the term confidential information shall not include
   information that:
    (i) is or  becomes  generally  available  to the  public  other  than  as a
          result of disclosure by receiving Party,
    (ii) was  available to receiving  Party on a  non-confidential  basis prior
          to its receipt from disclosing Party,
    (iii) becomes available to receiving Party lawfully from a third party that
          is not prohibited from disclosing such information, or
    (iv)  is developed independently by receiving Party as evidenced by written
          records other than through knowledge of the disclosed information from
          disclosing Party.

                        ARTICLE 10 (PUBLIC DISCLOSURE)
   When Corgenix wants to make any public disclosure in connection with this
   License Agreement, Corgenix shall propose such disclosure to Dr. Matsuura in
   writing. Dr. Matsuura shall have a right to review and edit such a proposed
   draft and a right to veto such a disclosure, but Dr. Matsuura cannot unduly
   withhold his consent. Dr. Matsuura shall respond to Corgenix within thirty
   (30) business days from the receipt of such a proposal.

ARTICLE 11 (WARRANTY AND INFRINGEMENT)
   11.1 Dr. Matsuura warrants that he has full authority to enter into this
   License Agreement, provided, however, that Dr. Matsuura makes no warranties,
   expressed or implied, as to the merchantability of the Technology nor
   warranties of freedom from infringement of any patents or other proprietary
   rights of third parties.

   11.2 In the event that any third party claim is made or suit is brought
   against Corgenix upon the basis that the manufacture, sale and use of the
   Licensed Product infringes a patent in the Territory owned by said third
   party, Dr. Matsuura, at his own discretion, will cooperate with Corgenix at
   Corgenix' cost as reasonably requested by Corgenix in defense of any such
   claims brought against Corgenix.

11.3   In the event that any third party infringes any of the Patents in the
       Territory, then the Parties hereto shall cooperate to take appropriate
       action against such third party.

ARITCLE 12 (INDEMNIFICATION)
   Corgenix shall indemnify Dr. Matsuura from and against any damages,
   liabilities, expenses to be suffered by Dr. Matsuura with regard to product
   liability claim by a third party.

ARTICLE 13 (TERM)
   This License Agreement, unless earlier terminated pursuant to Article 14
   thereof, shall continue in effect for a period of ten (10) years from the
   Effective Date, and may be renewed or extended for successive terms pursuant
   to terms and conditions mutually agreed upon in writing.

ARTICLE 14 (TERMINATION)
   Either Party may, without prejudice to any other rights or remedies,
   terminate the License Agreement by giving sixty (60) days written notice to
   the other with immediate effect, if any of the following events should occur
      (i)  if either Party fails to make any payment to the other when due under
           this License Agreement and such failure continues for more than
           thirty (30) days after receipt of a written notice specifying the
           default;
      (ii) if either Party fails to perform any other provision of this License
           Agreement which failure remains uncorrected for more than thirty (30)
           days after receipt of a written notice specifying the default;
      (iii) if either Party files a petition in bankruptcy, or petition in
           bankruptcy is filed against it, or either Party becomes insolvent,
           bankrupt, or makes a general assignment for the benefit of creditors,
           or goes into liquidation or receivership;
      (iv) if either Party ceases or threatens to cease to carry on business or
           disposes of the whole or any substantial part of its undertaking or
           its assets.

ARTICLE 15 (NOTICES)
   All notices or reports required or permitted under this License Agreement
   shall be in writing, and shall be given by prepaid registered airmail letter
   or international courier to the addresses shown below or to such other
   addresses as the parties may designate in writing.

   To Dr. Matsuura:
   ---------------
   Eiji Matsuura, Ph.D.
   ************* Japan
   To Corgenix:
   -----------
   Attention: President
   12061 Tejon Street
   Westminster, Colorado 80234 USA.

ARTICLE 16 (ENTIRE AGREEMENT)
   This License Agreement constitutes the entire agreement between Parties
   hereto, and supersedes any prior written or oral agreements between Parties
   concerning the subject matter hereof.

ARTICLE 17 (TITLES)
   The titles of the Articles of this License Agreement are for reference only,
   and this License Agreement shall not be construed by reference to such
   titles.

                           ARTICLE 18 (ARBITRATION)
   Any controversy or claim arising under or in relation to this License
   Agreement, except as otherwise expressly provided below, shall be settled
   exclusively by arbitration in accordance with the International Arbitration
   Rules of the American Arbitration Association (AAA). Arbitration shall take
   place in Denver, Colorado, U.S.A. before one arbitrator selected by the
   parties jointly or failing their agreement, selected pursuant to the rules of
   the AAA. The arbitration shall be conducted in English and shall use the U.S.
   Federal rules of evidence and the U.S. Federal rules of civil procedure. The
   substantially prevailing party shall be entitled to recover its costs and
   attorneys' fees. The decision of the arbitrators shall be final and binding
   on the parties, and judgment upon the award rendered by the arbitrators may
   be entered by any court having jurisdiction thereof. Dr. Matsuura
   specifically consents to the jurisdiction of the courts of the State of
   Colorado, U.S.A., and any other place where it is located or can be found for
   purposes of enforcing an award.

ARTICLE 19 (ASSIGNMENT)
   This License Agreement or any part of this License Agreement may not be
   assigned or transferred by either Party without the prior written consent of
   the other Party. Any assignment or transfer without such consent shall be
   null and void.

ARTICLE 20 (NO WAIVER)
   Except where specific time limits are herein provided, no delay on the part
   of either Party hereto in exercising any power or right hereunder shall
   operate as a waiver thereof, nor shall any single or partial exercise of any
   power or right hereunder preclude other or further exercise thereof or the
   exercise of any other power or right. No waiver, modification or amendment of
   this License Agreement or any provision hereof shall be enforceable against
   any party hereto unless in writing, signed by the Party against whom such
   waiver, modification or amendment is claimed, and with regard to any waiver,
   shall be limited solely to the one event.

ARTICLE 21 (GOVERNING LAW)
   This License Agreement shall be governed by and construed in accordance with
   the laws of Colorado.

   IN      CONSIDERATION OF the foregoing terms and conditions, Corgenix and Dr.
           Matsuura hereto have affixed their authorized signatures.

Corgenix Medical Corporation

s/ Luis R. Lopez, MD                s/ Eiji Matsuura, Ph.D.
--------------------                -----------------------
Luis R. Lopez, MD                   Eiji Matsuura, Ph.D.
CEO



<PAGE>


                                 CERTIFICATIONS

I, Luis R. Lopez, Chief Executive Officer, certify that:

1.     I have reviewed this quarterly report on Form 10-QSB of Corgenix
      Medical Corporation.

2.    Based on my knowledge, this quarterly report does not contain any untrue
      statement of a material fact or omit to state a material fact necessary to
      make the statements made, in light of the circumstances under which such
      statements were made, not misleading with respect to the period covered by
      this quarterly report.

3.    Based on my knowledge, the financial statements, and other financial
      information included in this quarterly report, fairly present in all
      material respects the financial condition, results of operations and cash
      flows of the registrant as of, and for, the periods presented in this
      quarterly report;

4.    The registrant's other certifying officers and I are responsible for
      establishing and maintaining disclosure controls and procedures (as
      defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we
      have:

(a)        designed such disclosure controls and procedures to ensure that
           material information relating to the registrant, including its
           consolidated subsidiaries, is made know to us by others within those
           entities, particularly during the period in which this quarterly
           report is being prepared;
(b)        evaluated the effectiveness of the registrant's disclosure controls
           and procedures as of a date within 90 days prior to the filing date
           of this quarterly report (the "Evaluation Date"); and
(c)        presented in this quarterly report our conclusions about the
           effectiveness of the disclosure controls and procedures based on our
           evaluation as of the Evaluation Date;

5.    The registrant's other certifying officers and I have disclosed, based on
      our most recent evaluation, to the registrant's auditors and the audit
      committee of registrant's board of directors:

(a)        all significant deficiencies in the design or operation of internal
           controls which could adversely affect the registrant's ability to
           record, process, summarize and report financial data and have
           identified for the registrant's auditors any material weaknesses in
           internal control; and
(b)        any fraud, whether or not material, that involves management or other
           employees who have a significant role in the registrant's internal
           controls; and

6.    The registrant's other certifying officers and I have indicated in this
      quarterly report whether or not there were significant changes in internal
      controls or in other factors that could significantly affect internal
      controls subsequent to the date of our most recent evaluation, including
      any corrective actions with regard to significant deficiencies and
      material weaknesses.

   Date:  November 14, 2002


         /S/Luis R. Lopez
         Chief Executive Officer












I, William H. Critchfield, Chief Financial Officer, certify that:

1.    I have reviewed this quarterly report on Form 10-QSB of Corgenix Medical
      Corporation.

2.    Based on my knowledge, this quarterly report does not contain any untrue
      statement of a material fact or omit to state a material fact necessary to
      make the statements made, in light of the circumstances under which such
      statements were made, not misleading with respect to the period covered by
      this quarterly report.

3.    Based on my knowledge, the financial statements, and other financial
      information included in this quarterly report, fairly present in all
      material respects the financial condition, results of operations and cash
      flows of the registrant as of, and for, the periods presented in this
      quarterly report;

4.    The registrant's other certifying officers and I are responsible for
      establishing and maintaining disclosure controls and procedures (as
      defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we
      have:

        (a) designed such disclosure controls and procedures to ensure that
           material information relating to the registrant, including its
           consolidated subsidiaries, is made know to us by others within those
           entities, particularly during the period in which this quarterly
           report is being prepared;
        (b) evaluated the effectiveness of the registrant's disclosure controls
           and procedures as of a date within 90 days prior to the filing date
           of this quarterly report (the "Evaluation Date"); and
        (c)presented in this quarterly report our conclusions about the
           effectiveness of the disclosure controls and procedures based on our
           evaluation as of the Evaluation Date;

5.    The registrant's other certifying officers and I have disclosed, based on
      our most recent evaluation, to the registrant's auditors and the audit
      committee of registrant's board of directors:

(a)        all significant deficiencies in the design or operation of internal
           controls which could adversely affect the registrant's ability to
           record, process, summarize and report financial data and have
           identified for the registrant's auditors any material weaknesses in
           internal control; and
(b)        any fraud, whether or not material, that involves management or other
           employees who have a significant role in the registrant's internal
           controls; and

6.    The registrant's other certifying officers and I have indicated in this
      quarterly report whether or not there were significant changes in internal
      controls or in other factors that could significantly affect internal
      controls subsequent to the date of our most recent evaluation, including
      any corrective actions with regard to significant deficiencies and
      material weaknesses.

   Date:  November 14, 2002


       /S/William H. Critchfield
       Chief Financial Officer















I, Douglass T. Simpson, President, certify that:

   1. I have reviewed this quarterly report on Form 10-QSB of Corgenix Medical
   Corporation.

2.    Based on my knowledge, this quarterly report does not contain any untrue
      statement of a material fact or omit to state a material fact necessary to
      make the statements made, in light of the circumstances under which such
      statements were made, not misleading with respect to the period covered by
      this quarterly report.

3.    Based on my knowledge, the financial statements, and other financial
      information included in this quarterly report, fairly present in all
      material respects the financial condition, results of operations and cash
      flows of the registrant as of, and for, the periods presented in this
      quarterly report;

4.    The registrant's other certifying officers and I are responsible for
      establishing and maintaining disclosure controls and procedures (as
      defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we
      have:

        (a) designed such disclosure controls and procedures to ensure that
           material information relating to the registrant, including its
           consolidated subsidiaries, is made know to us by others within those
           entities, particularly during the period in which this quarterly
           report is being prepared;
        (b) evaluated the effectiveness of the registrant's disclosure controls
           and procedures as of a date within 90 days prior to the filing date
           of this quarterly report (the "Evaluation Date"); and
(d)        presented in this quarterly report our conclusions about the
           effectiveness of the disclosure controls and procedures based on our
           evaluation as of the Evaluation Date;

5.    The registrant's other certifying officers and I have disclosed, based on
      our most recent evaluation, to the registrant's auditors and the audit
      committee of registrant's board of directors:

(a)        all significant deficiencies in the design or operation of internal
           controls which could adversely affect the registrant's ability to
           record, process, summarize and report financial data and have
           identified for the registrant's auditors any material weaknesses in
           internal control; and
(b)        any fraud, whether or not material, that involves management or other
           employees who have a significant role in the registrant's internal
           controls; and

6.    The registrant's other certifying officers and I have indicated in this
      quarterly report whether or not there were significant changes in internal
      controls or in other factors that could significantly affect internal
      controls subsequent to the date of our most recent evaluation, including
      any corrective actions with regard to significant deficiencies and
      material weaknesses.

   Date:  November 14, 2002


         /S/Douglass T. Simpson
         President













                                  CERTIFICATION
             PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
                       SUBSECTIONS (a) AND (b) OF SECTION 1350,
                     CHAPTER 63 OF TITLE 18, UNITED STATES CODE

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and
(b) of section 1350, chapter 63 of Title 18, United States Code), each of the
undersigned officers of Corgenix Medical Corporation, a Nevada corporation (the
"Company"), does hereby certify with respect to the Quarterly Report of the
Company on Form 10-QSB for the quarter ended September 30, 2002 as filed with
the Securities an Exchange Commission (the "10-QSB Report") that:

(1)        the 10-QSB Report fully complies with the requirements of section
           13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)        the information contained in the 10-QSB Report fairly presents, in
           all material respects, the financial condition and results of
           operations of the Company.


Dated:     November 14, 2002



/S/Luis R. Lopez
Chief Executive Officer


/S/William H. Critchfield
Chief Financial Officer


/S/Douglass T. Simpson
President



                                   SIGNATURES


      In accordance with the requirements of the Securities Exchange Act of
1934, the registrant caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.



                                    CORGENIX MEDICAL CORPORATION



November 14, 2002                              By: /s/ Luis R. Lopez
                                               -------------------
                                               Luis R. Lopez, M.D.
                                               Chairman and Chief
                                               Executive Officer